Research and development of human neutralizing antibodies aiming at treatment of non-small cell lung carcinoma

2014 Fiscal Year Final Research Report

• Project/Area Number: 24590490
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Experimental pathology
• Research Institution: Keio University
• Principal Investigator: MOCHIZUKI Satsuki 慶應義塾大学, 医学部, 講師 (80365428)
• Co-Investigator(Renkei-kenkyūsha): OKADA Yasunori 慶應義塾大学, 医学部, 教授 (00115221)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: ADAM / 分子標的 / 肺癌

Outline of Final Research Achievements

ADAM28, a member of the ADAM (a disintegrin and metalloproteinase) gene family, plays an important role in cancer cell proliferation and metastasis. In the present study, we screened Human Combinatorial Antibody Library by phage display panning and　obtained antibodies (211-14 and 211-12) against ADAM28. Tumor growth and metastasis of the lung tumors after intravenous injection of PC-9 ffLuc-cp156 lung carcinoma cells were significantly inhibited by the antibody treatment, improving survival rate of the mice. These data indicate that our antibodies 211-14 and 211-12 neutralize ADAM28 activity and antibody 211-14 inhibits cancer cell proliferation and metastasis in vivo. The antibodies could be used as an ADAM28 inhibitor for clinical application to treat the patients with lung or breast carcinoma in the future.

Free Research Field

癌細胞増殖・転移、メタロプロテアーゼ、細胞外マトリックス